Kiniksa Pharmaceuticals International, plc (KNSA) stock
KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30469% above fair value
$95.05−0.06 (-0.06%)
Close on Nov 18, 2026Market cap $14.94BP/E 73.1Yield –
Kiniksa Pharmaceuticals International operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Kiniksa Pharmaceuticals International's operating income for the twelve months ending Sep 30, 2026 was $130.47M, up 241.9% year over year. For fiscal 2025 it was $77.22M. The highest annual figure on record is $77.22M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.22M | – |
| FY2024 | Dec 31, 2024 | -$45.62M | – |
| FY2023 | Dec 31, 2023 | -$25.20M | -357.8% |
| FY2022 | Dec 31, 2022 | $9.77M | – |
| FY2021 | Dec 31, 2021 | -$156.64M | – |
| FY2020 | Dec 31, 2020 | -$157.36M | – |
| FY2019 | Dec 31, 2019 | -$169.96M | – |
| FY2018 | Dec 31, 2018 | -$108.16M | – |
| FY2017 | Dec 31, 2017 | -$65.40M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $54.24M | +125.8% |
| Q2 FY2026 | Jun 30, 2026 | $27.19M | +34.9% |
| Q1 FY2026 | Mar 31, 2026 | $29.27M | +120.5% |
| Q4 FY2025 | Dec 31, 2025 | $19.77M | – |
| Q3 FY2025 | Sep 30, 2025 | $24.02M | – |
| Q2 FY2025 | Jun 30, 2025 | $20.16M | – |
| Q1 FY2025 | Mar 31, 2025 | $13.27M | – |
| Q4 FY2024 | Dec 31, 2024 | -$19.30M | -23925.9% |
| Q3 FY2024 | Sep 30, 2024 | -$9.66M | – |
| Q2 FY2024 | Jun 30, 2024 | -$117.00K | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.54M | – |
| Q4 FY2023 | Dec 31, 2023 | $81.00K | -98.7% |
| Q3 FY2023 | Sep 30, 2023 | -$10.93M | -123.5% |
| Q2 FY2023 | Jun 30, 2023 | -$3.15M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.20M | – |
| Q4 FY2022 | Dec 31, 2022 | $6.05M | – |
| Q3 FY2022 | Sep 30, 2022 | $46.41M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.37M | – |
| Q1 FY2022 | Mar 31, 2022 | -$23.32M | – |
| Q4 FY2021 | Dec 31, 2021 | -$36.13M | – |
| Q3 FY2021 | Sep 30, 2021 | -$30.67M | – |
| Q2 FY2021 | Jun 30, 2021 | -$40.56M | – |
| Q1 FY2021 | Mar 31, 2021 | -$49.28M | – |
| Q4 FY2020 | Dec 31, 2020 | -$52.90M | – |
| Q3 FY2020 | Sep 30, 2020 | -$43.22M | – |
| Q2 FY2020 | Jun 30, 2020 | -$31.86M | – |
| Q1 FY2020 | Mar 31, 2020 | -$29.39M | – |
| Q4 FY2019 | Dec 31, 2019 | -$32.58M | – |
| Q3 FY2019 | Sep 30, 2019 | -$30.45M | – |
| Q2 FY2019 | Jun 30, 2019 | -$39.29M | – |
| Q1 FY2019 | Mar 31, 2019 | -$67.65M | – |
| Q4 FY2018 | Dec 31, 2018 | -$44.14M | – |
| Q3 FY2018 | Sep 30, 2018 | -$26.16M | – |
| Q2 FY2018 | Jun 30, 2018 | -$21.53M | – |
| Q1 FY2018 | Mar 31, 2018 | -$16.34M | – |
| Q4 FY2017 | Dec 31, 2017 | -$32.71M | – |
| Q3 FY2017 | Sep 30, 2017 | -$16.25M | – |
| Q2 FY2017 | Jun 30, 2017 | -$11.39M | – |
See a number that looks wrong?